CAPRICOR THERAPEUTICS, INC. - 8-K Filing
Capricor Therapeutics reported first-quarter 2026 financial results with $278.6 million cash, a net loss of $33.9 million ($0.59 per share), and no revenue recognized for the quarter. The company's Biologics License Application (BLA) for Deramiocel is under FDA review with an August 22 PDUFA date; it also filed legal action against NS Pharma over a flawed distribution agreement, and plans to hire a Chief Commercial Officer with DMD experience soon. (Items: 2.02 of this Current Report on Form 8-K and Exhibit 99)
Tickers: $CAPR